A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

被引:6
作者
Jhaveri, Komal [1 ]
Juric, Dejan [2 ]
Saura, Cristina [3 ]
Cervantes, Andres [4 ]
Melnyk, Anton [5 ]
Patel, Manish R. [6 ]
Oliveira, Mafalda [3 ]
Gambardella, Valentina [4 ]
Ribrag, Vincent [7 ]
Ma, Cynthia X. [8 ]
Aljumaily, Raid [9 ]
Bedard, Philippe L. [10 ]
Sachdev, Jasgit C. [11 ]
Bond, John [12 ]
Jones, Surai [12 ]
Wilson, Timothy R. [12 ]
Wei, Michael C. [12 ]
Baselga, Jose [1 ]
机构
[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain
[4] Univ Valencia, Inst Hlth Res INCLIVA, CIBERONC, Valencia, Spain
[5] Texas Oncol Abilene, Abilene, TX USA
[6] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[7] Inst Gustave Roussy, Villejuif, France
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[10] Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] TGen, Honor Hlth Res Inst, Scottsdale, AZ USA
[12] Genentech Inc, San Francisco, CA 94080 USA
关键词
D O I
10.1158/1538-7445.AM2018-CT046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CT046
引用
收藏
页数:2
相关论文
共 50 条
[21]   SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors [J].
Baselga, J. ;
Cortes, J. ;
De laurentiis, M. ;
Dent, S. ;
Dieras, V. ;
Harbeck, N. ;
Hsu, J. ;
Jin, H. ;
Schimmoller, F. ;
Wilson, T. R. ;
Im, Y-H ;
Jacot, W. ;
Krop, I. E. ;
Verma, S. .
CANCER RESEARCH, 2017, 77
[22]   Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer [J].
Saura, Cristina ;
Sachdev, Jasgit ;
Patel, Manish R. ;
Cervantes, Andres ;
Juric, Dejan ;
Infante, Jeffrey R. ;
Richards, Donald ;
Sanabria, Sandra ;
Lu, Xuyang ;
Ware, Joseph ;
Wilson, Timothy R. ;
Parmar, Hema ;
Hsu, Jerry Y. ;
Oliveira, Mafalda ;
Winer, Eric P. ;
Von Hoff, Daniel D. ;
Baselga, Jose ;
Krop, Ian E. .
CANCER RESEARCH, 2015, 75
[23]   Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors [J].
Juric, Dejan ;
Krop, Ian ;
Ramanathan, Ramesh K. ;
Wilson, Timothy R. ;
Ware, Joseph A. ;
Bohorquez, Sandra M. Sanabria ;
Savage, Heidi M. ;
Sampath, Deepak ;
Salphati, Laurent ;
Lin, Ray S. ;
Jin, Huan ;
Parmar, Hema ;
Hsu, Jerry Y. ;
Von Hoff, Daniel D. ;
Baselga, Jose .
CANCER DISCOVERY, 2017, 7 (07) :704-715
[24]   Discovery and development of a new commercial route for a key regulatory starting material in the synthesis of PI3k β-sparing inhibitor GDC-0032 (Taselisib) [J].
Beaudry, Danial R. .
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[25]   Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer [J].
Savage, Heidi M. ;
O'Brien, Carol ;
Yauch, Bob ;
Settleman, Jeff ;
Lackner, Mark R. ;
Wilson, Timothy R. .
CANCER RESEARCH, 2014, 74 (19)
[26]   Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor [J].
Wilson, Timothy R. ;
Savage, Heidi ;
O'Brien, Carol ;
Sanabria, Sandra ;
Lin, Ray S. ;
Wagle, Marie-Claire ;
Yan, Yibing ;
Lackner, Mark R. ;
Parmar, Hema ;
Hsu, Jerry Y. ;
Juric, Dejan ;
Krop, Ian E. ;
Ramanathan, Ramesh K. ;
Von Hoff, Daniel D. ;
Baselga, Jose .
CANCER RESEARCH, 2014, 74 (19)
[27]   The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models [J].
Sampath, D. ;
Nannini, M. A. ;
Jane, G. ;
Hong, R. ;
Parsons, K. L. ;
Belvin, M. ;
Friedman, L. S. ;
Wallin, J. J. .
CANCER RESEARCH, 2013, 73
[28]   Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study) [J].
Kobayashi, T. ;
Nakano, K. ;
Tomomatsu, J. ;
Nara, E. ;
Ito, Y. ;
Kobayashi, K. ;
Fukada, I. ;
Araki, K. ;
Shimomura, A. ;
Shimoi, T. ;
Kodaira, M. ;
Yunokawa, M. ;
Yonemori, K. ;
Shimizu, C. ;
Nakamura, K. ;
Kotani, N. ;
Inatani, M. ;
Tamura, K. ;
Takahashi, S. .
CANCER RESEARCH, 2016, 76
[29]   A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2-advanced breast cancer [J].
Wu, Jiong ;
Zhang, Jian ;
Li, Man ;
Cai, Li ;
Sun, Tao ;
Ouyang, Quchang ;
Meng, Yanchun ;
Shi, Yehui ;
Wang, Chuan ;
Liu, Qiang ;
Lu, Yongkui ;
Yin, Yongmei ;
Chen, Qianjun ;
Chen, Lilin ;
Wang, Haitao ;
Cui, Jiuwei ;
Liao, Ning ;
Wang, Shubin ;
Tu, Yi ;
Yan, Min .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30]   The P13K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors [J].
Wallin, J. J. ;
Edgar, K. A. ;
Guan, J. ;
Sampath, D. ;
Nannini, M. ;
Belvin, M. ;
Friedman, L. S. .
CANCER RESEARCH, 2013, 73